Industry News
Biotechnology Industry News
UPDATE: Aptinyx pauses phase 2 trial of higher dose PTSD med to save cash
UPDATE: Aptinyx pauses phase 2 trial of higher dose PTSD med to save cash mbayer Wed, 04/20/2022 - 11:30
Windtree’s phase 2 shock med rapidly raises blood pressure—and share price
Windtree's phase 2 shock med rapidly raises blood pressure—and share price aarmstrong Wed, 04/20/2022 - 09:34
Arcturus’ stock sinks after self-amplifying COVID-19 mRNA vaccine posts 55% efficacy in phase 3
Arcturus' stock sinks after self-amplifying COVID-19 mRNA vaccine posts 55% efficacy in phase 3 ntaylor Wed, 04/20/2022 - 08:20
AbbVie shreds alpha-synuclein Parkinson’s pact on cusp of phase 2, thinning field led by Roche
AbbVie shreds alpha-synuclein Parkinson's pact on cusp of phase 2, thinning field led by Roche ntaylor Wed, 04/20/2022 - 06:55
Satellite Bio lifts off with $110M to fuel development of its implantable tissue therapies
Satellite Bio lifts off with $110M to fuel development of its implantable tissue therapies mbayer Wed, 04/20/2022 - 00:30
Tessera Therapeutics stacks up more than $300M in series C funds to bolster new gene-editing platforms
Tessera Therapeutics stacks up more than $300M in series C funds to bolster new gene-editing platforms mbayer Tue, 04/19/2022 - 16:29
BioXcel will use $260M finance deal to expand indications for schizophrenia drug
BioXcel will use $260M finance deal to expand indications for schizophrenia drug gmasson Tue, 04/19/2022 - 15:57
Finch’s nest thins out with 20% of employees cut in restructuring after FDA hold
Finch's nest thins out with 20% of employees cut in restructuring after FDA hold aarmstrong Tue, 04/19/2022 - 09:54
Imara eliminates 83% of workforce—including chief medical officer—in wake of pipeline wipeout
Imara eliminates 83% of workforce—including chief medical officer—in wake of pipeline wipeout gmasson Tue, 04/19/2022 - 09:54
Regeneron sees skin cancer potential beyond PD-1s with $250M Checkmate acquisition
Regeneron sees skin cancer potential beyond PD-1s with $250M Checkmate acquisition jwaldron Tue, 04/19/2022 - 09:07
Axsome moves ‘closer to judgement day’ for stalled depression therapy
Axsome moves 'closer to judgement day' for stalled depression therapy aarmstrong Tue, 04/19/2022 - 08:54
Moderna’s bivalent beta booster betters Spikevax versus omicron, pointing to promise of variant-specific jabs
Moderna's bivalent beta booster betters Spikevax versus omicron, pointing to promise of variant-specific jabs ntaylor Tue, 04/19/2022 - 08:09
Ouch! Acadia’s non-opioid painkiller flunks midphase test, weakening a potential rival to Vertex
Ouch! Acadia's non-opioid painkiller flunks midphase test, weakening a potential rival to Vertex ntaylor Tue, 04/19/2022 - 04:38
Sionna unveils with $111M series B to pursue quest for ‘holy grail’ cystic fibrosis target
Sionna unveils with $111M series B to pursue quest for 'holy grail' cystic fibrosis target mbayer Tue, 04/19/2022 - 01:41
Fore tees up new CEO, 5 months after ousting former chief executive on insider trading charges
Fore tees up new CEO, 5 months after ousting former chief executive on insider trading charges gmasson Mon, 04/18/2022 - 11:27
With IL-12 prospect nearing clinic, Ankyra inks NCI pact to support cancer pipeline progress
With IL-12 prospect nearing clinic, Ankyra inks NCI pact to support cancer pipeline progress ntaylor Mon, 04/18/2022 - 08:47
Emergex’s synthetic T-cell adaptive vaccines close in on data in dengue, COVID-19
Emergex's synthetic T-cell adaptive vaccines close in on data in dengue, COVID-19 ntaylor Mon, 04/18/2022 - 08:13
U2 disbands: In a crushing step back, TG retracts FDA request for combo therapy due to death risk
U2 disbands: In a crushing step back, TG retracts FDA request for combo therapy due to death risk mbayer Fri, 04/15/2022 - 10:38
UPDATE: TG disbands cancer program after pulling FDA request for U2 combo therapy
UPDATE: TG disbands cancer program after pulling FDA request for U2 combo therapy mbayer Fri, 04/15/2022 - 10:38
Dutch courage: Netherlands makes $350M bet on patient-centered preclinical cancer drug development
Dutch courage: Netherlands makes $350M bet on patient-centered preclinical cancer drug development ntaylor Fri, 04/15/2022 - 03:27